A hypothesis is a clearly formulated, testable assumption about a research question or a treatment effect in clinical research. In confirmatory clinical trials, it is specified prior to the start of the trial and linked to the primary objective, the endpoints, the sample size planning and the statistical analysis. It thus creates a traceable framework for the conclusion the trial is intended to support. It also prevents an assumption developed only after reviewing the data from appearing as prospectively confirming evidence.
Confirmatory and exploratory hypotheses
At the beginning is a clinically significant question: For which population, under which treatment conditions, should which benefit or risk be assessed? ICH E9(R1) requires translating this question into an estimand. This describes the treatment effect to be estimated and also considers events after the start of treatment, such as treatment discontinuation, additional medication or death, insofar as they are relevant for the research question.
The statistical hypothesis turns this into a testable comparison. It should reveal treatment groups, endpoint, target population, direction of comparison and, if applicable, a relevant margin. A vague statement such as “the medicinal product works” is not sufficient. The protocol must clearly state the scientific objectives; the statistical analysis plan defines the technical details of the analysis before the blind is broken.
In confirmatory trials, the central hypothesis is directly linked to the primary study objective. Its testing is intended to provide robust evidence, which is why endpoint, analysis, handling of missing data and multiple testing are planned prospectively. Changes after knowledge of the treatment results can considerably weaken interpretability and must be transparently documented if they are unavoidable.
Exploratory trials and exploratory analyses fulfill a different function. They can investigate doses, target populations, endpoints or possible subgroups and thereby justify subsequent research. New hypotheses can emerge from data-driven observations; however, they are not equivalent to prospectively confirming tests. The separation of confirmatory and exploratory aspects must remain recognizable in the protocol and in the report.
Distinction from the null hypothesis (H0)
Hypothesis is the umbrella term. A null hypothesis, usually called H0, is the specific statistical assumption against which a test is directed. In a test for difference, it frequently states that there is no difference in the metric of interest between the treatment groups. The alternative hypothesis describes the counter-position compatible with the study objective, for instance a difference or a benefit.
A non-statistically significant result does not prove H0. It merely means that the data do not provide sufficient evidence against H0 under the predefined procedure. Likewise, a small p-value is not a complete answer to the clinical question: effect size, confidence interval, data quality and the predefined estimand remain essential. The null hypothesis is therefore a tool of test logic, not synonymous with the entire study objective.
Hypothesis, estimand and analysis
A well-formulated hypothesis must align with the effect to be estimated and the analysis. The estimand answers which effect is of interest under clearly described conditions; the estimator is the method by which it is estimated from trial data; the estimate is the resulting numerical value. Confidence intervals and tests support the assessment of uncertainty, but do not replace the precise definition of the effect.
The hypothetical strategy within the estimand framework is not a synonym for a hypothesis. It describes how a treatment effect is handled under a not directly observed scenario, for example as if an additional therapy had not been initiated. Whether such a strategy fits the clinical question must be justified in advance and safeguarded by appropriate assumptions and sensitivity analyses.
Relevance for clinical trials
The hypothesis guides practical decisions from the choice of control, through endpoint and analysis population, to sample size. Unclear or retrospectively shifted hypotheses increase the risk of selective analyses and complicate regulatory assessment. It is important for trial quality that protocol, analysis plan, data collection and report reflect the same central question.
Full-service CROs such as Mediconomics support with the translation of clinical objectives into precise endpoint and estimand descriptions, with sample size planning and with the statistical analysis plan. They coordinate contributions from medical planning, data management, biostatistics and medical writing so that predefined hypotheses, analyses and reporting documents are consistently documented.
Frequently Asked Questions (FAQ)
Is every study question a hypothesis?
A research question can be descriptive or exploratory. A confirmatory hypothesis requires a precise, prospectively testable formulation and a matching analysis plan.
Does a significant test prove the alternative hypothesis?
It provides evidence against the null hypothesis under the model assumptions. The clinical interpretation additionally requires effect size, precision and quality assessment.
May a hypothesis be changed after the start of the trial?
Changes must be justified, documented and clearly separated from confirmatory analyses. After unblinding, they are particularly critical.
Regulatory references
- ICH E9, Statistical Principles for Clinical Trials — describes prospectively formulated hypotheses in confirmatory trials.
- ICH E9(R1), Addendum on Estimands and Sensitivity Analysis in Clinical Trials — connects study objective, estimand and analysis.
- ICH E8(R1), General Considerations for Clinical Studies — requires clearly articulated objectives and scientifically valid hypotheses.
- ICH E6(R3), Guideline for Good Clinical Practice — requires clear study objectives and a documented analysis plan.